Event Information :

CAR-T cell therapy has revolutionized the treatment of hematological cancers, but solid tumors present formidable challenges, largely due to their complex and immunosuppressive tumor microenvironment. A key driver of this environment is angiogenesis, often mediated by the VEGF pathway, which supplies tumors with nutrients and inhibits immune cell function. To overcome this barrier, innovative strategies are emerging to "armor" CAR-T cells, enabling them to function as "living drugs" that not only kill cancer cells but also actively remodel the tumor microenvironment.

We are honored to invite Dr. Mark Leick to introduce a novel approach that leverages CAR-T cells for the targeted delivery of anti-VEGF therapeutics. Join us to explore how these engineered CAR-T cells (CARVEGF) function as "Trojan horses" to unleash a dual-pronged attack: directly targeting tumor cells while simultaneously delivering localized VEGF blockade to disrupt tumor angiogenesis. This strategy enhances CAR-T cell activity and proliferation, demonstrating significant in vivo potency in challenging solid tumor models.

During this webinar, we will discuss the following key points:

• Activated CAR-T cells upregulate VEGF pathway members
• CARVEGF have enhanced in vitro anti-tumor activity and proliferation
• CARVEGF have enhanced in vivo potency in immunocompromised mouse models of metastatic ovarian and lung cancer
• 70VEGF cells target delivery of VEGF blockade within an orthotopic RCC model in immunocompromised mice

Register at https://www.creative-biolabs.com/car-t/car-t-cell-targeted-delivery-of-secreted-therapeutics-for-solid-tumors.htm

Free